The integration of the two technology transfer activities created a single organisation focused on delivering the complete commercialisation process from patent registration and support for the creation of new businesses, through to licensing and sales of technologies to industry partners.

[4] UCLB provided advice and a grant support to Siavash Haroun Mahdavi in helping him to establish the robotics company Complex Matters.

[5] In January 2011, BioVex, a cancer vaccines company spun-out of UCL in 1999, was sold to Amgen for $1 billion.

[6][7] UCLB has equity stake in all of its companies, the majority being spin-outs arising from technologies developed across the full range of faculties within UCL, including biomedical, biotechnology, engineering, mathematics, physical sciences and build environment companies.

These include Ark Therapeutics Ltd, Arrow Therapeutics Ltd, Biovex Ltd, Canbex, Domainex Ltd, Evexar Medical Ltd, Genex Biosystems, Intercytex, Medic-to-Medic, Pentraxin Therapeutics, PolyMASC Pharmaceuticals PLC, Proaxon, Spirogen Ltd, Stanmore Implants Worldwide Ltd,[8] Advanced Design Technology, AS Built Solutions, Bloomsbury DSP, Endomagnetics, EuroTempest, Ixico, Quantemol, Senceive, Space Syntax, Zinwave.